Korean J Hematol.  2012 Sep;47(3):157-158. 10.5045/kjh.2012.47.3.157.

Targeting the protein kinases for anti-cancer therapy

• Bang SM

• KMID: 2251946
• DOI: http://doi.org/10.5045/kjh.2012.47.3.157

Abstract

No abstract available.

MeSH Terms

Protein Kinases
Protein Kinases

Reference

1. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science. 2004. 303:1800–1805.

2. Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer. 2009. 9:28–39.

3. Paul MK, Mukhopadhyay AK. Tyrosine kinase - role and significance in cancer. Int J Med Sci. 2004. 1:101–115.

4. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005. 4:988–1004.

5. Farag SS. The potential role of Aurora kinase inhibitors in haematological malignancies. Br J Haematol. 2011. 155:561–579.

6. Sasai K, Katayama H, Stenoien DL, et al. Aurora-C kinase is a novel chromosomal passenger protein that can complement Aurora-B kinase function in mitotic cells. Cell Motil Cytoskeleton. 2004. 59:249–263.

7. Katayama H, Sasai K, Kawai H, et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet. 2004. 36:55–62.

8. Kim SJ, Jang JE, Cheong JW, et al. Aurora A kinase expression is increased in leukemia stem cells, and a selective Aurora A kinase inhibitor enhances Ara-C-induced apoptosis in acute myeloid leukemia stem cells. Korean J Hematol. 2012. 47:178–185.

9. Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside in patients with acute myeloid leukemia (AML). Blood. 2010. 116:abst656.